Health X Platform Limited will host an earnings conference call on Tuesday, August 11, 2026, at 4:00 PM IST to discuss its financial performance and business updates for the first quarter of FY27 (Q1FY27). The session provides investors and analysts with a direct channel to management regarding the company’s results for the quarter ended June 30, 2026.

The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Health X Platform Limited, formerly known as Sastasundar Ventures Limited, submitted the intimation to the BSE Limited and The National Stock Exchange of India Ltd. on August 5, 2026. The company emphasized that only information available in the public domain will be shared during the interaction, ensuring no unpublished price-sensitive information is disclosed.

Key Participants and Host

The conference call is hosted by Go India Advisors. The following senior executives are confirmed to participate in the discussion:

Call Access and Registration

Investors and analysts must pre-register to receive login details for the virtual session. The company has provided universal dial-in numbers for those preferring audio access via telephone. The schedule is subject to change due to exigencies on the part of the analysts or investors.

For further assistance, participants may contact Sheetal Khanduja or Soumya Chhajer at Go India Advisors. The company’s registered office is located at Azimganj House, Kolkata, and it operates under the Scrip Code 533259 on BSE and Symbol HEALTHX on NSE.

Health X Platform Limited has resolved a significant legal dispute with the tax authorities, receiving a final order from the Customs, Excise and Service Tax Appellate Tribunal (CESTAT) that fully favors the company. The tribunal allowed the appeal filed against the Commissioner of Service Tax, Kolkata, setting aside a demand for ₹65,19,360 related to alleged non-payment of service tax, education cess, and higher education cess under the Finance Act, 1994. This resolution eliminates any potential financial liability or penalty exposure for Health X Platform, providing clarity on a matter that had been pending since 2014.

The litigation was initiated on June 23, 2014, when the company filed an appeal against an order passed by the Commissioner of Service Tax. The dispute centered on allegations of contravention of the Finance Act, 1994 provisions. Over the years, the case saw multiple hearing dates, including rescheduled sessions in January, March, May, June, July, September, and December of 2025, as well as March 2026. The most recent hearing prior to the verdict was scheduled for June 15, 2026, but the authority pronounced its final decision earlier.

The CESTAT delivered its final order on July 30, 2026, which the company received on August 3, 2026. In its ruling, the authority held that the impugned demand of service tax was not sustainable. Consequently, the tribunal set aside the entire demand and explicitly stated that no penalties are imposable on the company. The appeal was allowed with consequential relief, if any, ensuring that Health X Platform faces no adverse financial consequences from this specific litigation.

This update was disclosed by the company to the Bombay Stock Exchange and the National Stock Exchange of India Limited under Regulation 30 of the SEBI Listing Regulations. The disclosure aligns with the requirements of sub-para 8 of para B of Part A of Schedule III, read with Annexure 18 of the Master Circular dated November 11, 2024, regarding ongoing tax litigations and disputes.

Litigation Timeline and Details

What the Numbers Show

The resolution of this case is entirely positive for Health X Platform’s balance sheet. With the CESTAT ruling that the demand is not sustainable, the company avoids an immediate cash outflow of ₹65,19,360. More importantly, the explicit statement that "no penalties are imposable" removes the risk of additional financial burdens that often accompany tax disputes. Since there is no material financial impact, this outcome does not alter the company’s current fiscal projections but does improve its legal risk profile by closing a long-standing chapter of regulatory uncertainty.